DrugsControl Media Services
DrugsControl.org

News Detail

Bayer initiates Phase II study with anti-alpha2 antiplasmin antibody in patients with DVT (25-02-2024)

BERLIN, 25 FEB 2024: Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT). The results of this study might......
View Details

Source : BioSpace
dissolving blood clots deep vein thrombosis (DVT) anti-alpha 2 antiplasmin antibody Bayer 

Related News